Infinity Acquisition (Fort Lauderdale, Florida) reported that it has changed its name to Younger America and has been approved for a symbol change to commence trading under the new symbol YNGR.

Younger America is a holding company that develops and acquires undervalued companies that provide products and services to improve the quality of life without the use of potentially harmful drugs or chemicals. The company aims to acquire a portfolio of companies that provide leading edge alternative medical devices, systems and services. The roll up of these companies will create value for the shareholders and provide innovative technologies and products that can enhance the quality of life for people. The initial products will include drug free pain therapy devices, and minimally-invasive medical and aesthetic cosmetic procedures.

Organogenesis moving to Massachusetts

Organogenesis (Canton, Massachusetts), a biotechnology company that makes living artificial skin, plans to build a new headquarters and factory in Massachusetts and add 300 jobs over the next five years after the state offered it an incentive package worth up to $18 million, the company said.

Four years after emerging from bankruptcy, the privately held Organogenesis now has annual sales of about $50 million and is looking to expand from the wound-healing product into new arenas such as cosmetic skin care.

Organogenesis had been planning to expand in Rhode Island, said its CEO, Geoff MacKay, and had also considered Connecticut. But after months of meetings, Massachusetts business-development officials put together a deal to keep the company in the state.

The state will provide $12.9 million in grants and infrastructure support to Organogenesis, plus as much as $5 million in low-interest loans. The exact mix of grants and other incentives has yet to be worked out.

New building for American Medical

American Medical Systems Holdings (Minneapolis), makers of pelvic health solutions, will celebrate the grand opening of a new building. The new building — adjacent to its existing facility — signifies the company’s expanded revenue and employee base and adds over 50,000 square feet of new office space to the AMS campus.

“The decision to expand our Minnesota facility demonstrates our long-term commitment to the region and its world-class lifescience industry,” said Martin Emerson, president/CEO of AMS. “With the state’s well-educated and technically skilled workforce, AMS continues to attract competitive and committed employees who drive the success of the organization.”

University of Pittsburgh to use TriCipher online

The University of Pittsburgh Medical Center (UPMC) will use TriCipher ’s (Los Gatos, California) multifactor authentication solution to protect access to personal health information on its online patient healthcare portal and physician network — putting the medical center at the forefront of aggressively protecting patients’ identities.

The $6 billion medical center’s web site portal will become the central information access point for more than 4 million patients worldwide. In addition, doctors will have secure access to patient health data across the entire medical center, improving patient care and increasing the efficiency of the medical center.

TriCipher provides a unified authentication infrastructure to protect the B2B and B2C online channel against fraud and identity theft.

LifeWatch subsidiary issued a CMS number

LifeWatch (Chicago) reported that its subsidiary, LifeWatch services, has been issued a CMS (Medicare) provider number for its IDTF patient monitoring center in Philadelphia, and approval to bill for its LifeStar ACT ambulatory cardiac telemetry services. The approval was granted by Highmark, the Pennsylvania carrier for Medicare, and is retroactive to October 2006.

“This is a tremendous milestone for Lifewatch, and will allow us to expand the LifeStar ACT ambulatory cardiac telemetry service,” stated Frederick Mindermann, LifeWatch Corp. president/CEO.

LifeWatch, through its operating subsidiaries Lifewatch Services, and LifeWatch Technologies, (Instromedix) is an independent provider of ambulatory cardiac monitoring services and a manufacturer and distributor of ambulatory cardiac and vital signs monitoring devices in the U.S.

Corautus gets NASDAQ non-compliance letter

Corautus Genetics (Atlanta) said that, as expected, it received a letter from the NASDAQ Stock Market formally notifying Corautus that it did not regain compliance with the minimum $1 price requirement for continued listing set forth in NASDAQ Marketplace Rule 4310(c)(4) during the 180-day period previously provided to Corautus under NASDAQ listing rules.

Corautus did not evidence compliance with the minimum bid price requirement by the Nov. 21, 2006 deadline. However, Corautus was advised by NASDAQ on Nov. 22, 2006, that because Corautus met all applicable initial inclusion criteria for the NASDAQ capital market at that time except for bid price, in accordance with applicable NASDAQ rules, Corautus was provided an additional 180 calendar-day compliance period, through May 21, 2007, to evidence compliance. Corautus did not regain compliance during this additional compliance period.